For research use only. Not for therapeutic Use.
Honokiol DCA (Honokiol dichloroacetate) is a dichloroacetate analog of Honokiol. Honokiol DCA can inhibit the growth of human prostate cancer cells in vitro and suppress the androgen receptor (AR) protein level[1].
Honokiol DCA (20-40 μM; 24-48 h) inhibits the viability of LNCaP and C4-2 cells in a dose-and time-dependent manner[1].
Honokiol DCA (5-20 μM; 10 days) inhibits clonogenicity of prostate cancer cells[1].
Honokiol DCA (20-40 μM; 24-48 h) significantly decreases the level of androgen receptor (AR) and prostate specific antigen (PSA) protein in LNCaP cells[1].
Honokiol DCA (40 μM; 24 h) significantly decreases AR promoter activity in LNCaP and C4-2 cells[1].
Honokiol类似物
| Catalog Number | I028864 |
| CAS Number | 1620160-42-0 |
| Synonyms | [4-[2-(2,2-dichloroacetyl)oxy-5-prop-2-enylphenyl]-2-prop-2-enylphenyl] 2,2-dichloroacetate |
| Molecular Formula | C22H18Cl4O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C22H18Cl4O4/c1-3-5-13-7-9-18(30-22(28)20(25)26)16(11-13)14-8-10-17(15(12-14)6-4-2)29-21(27)19(23)24/h3-4,7-12,19-20H,1-2,5-6H2 |
| InChIKey | KSJLHVAHFGNFFU-UHFFFAOYSA-N |
| SMILES | C=CCC1=CC(=C(C=C1)OC(=O)C(Cl)Cl)C2=CC(=C(C=C2)OC(=O)C(Cl)Cl)CC=C |
| Reference | [1]. Hahm ER, et, al. Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate. 2014 Apr;74(4):408-20. |
